Avenue Therapeutics, Inc.

NasdaqCM ATXI

Avenue Therapeutics, Inc. Free Cash Flow Yield on January 14, 2025

Avenue Therapeutics, Inc. Free Cash Flow Yield is NA on January 14, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Avenue Therapeutics, Inc. 52-week high Free Cash Flow Yield is -71.56% on April 08, 2024, which is NA below the current Free Cash Flow Yield.
Avenue Therapeutics, Inc. 52-week low Free Cash Flow Yield is -245.13% on June 21, 2024, which is NA below the current Free Cash Flow Yield.
Avenue Therapeutics, Inc. average Free Cash Flow Yield for the last 52 weeks is -160.34%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: ATXI

Avenue Therapeutics, Inc.

CEO	Dr. Alexandra MacLean M.D.
IPO Date	June 27, 2017
Location	United States
Headquarters	1140 Avenue of the America
Employees	3
Sector	Health Care
Industries Pharmaceuticals

Description

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Key trends

Past 5 years